Pyxis Oncology at ENA 2026
Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website
Pyxis Oncology brings 2 presentations to ENA 2026 in Barcelona. Its posters centre on micvotabart pelidotin, an antibody-drug conjugate targeting extradomain-B of fibronectin. They cover how the drug works in vitro and how adding EGFR-targeted therapy improves duration of response in HNSCC patient-derived xenograft models.
| Organization | ENA 2026 Attendance |
|---|---|
Pyxis Oncology Boston, MA | |
Clinical-stage company developing antibody-drug conjugates, including micvotabart pelidotin targeting extradomain-B of fibronectin. | Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm |
Instantly find 20 buyers from Pyxis Oncology
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by EORTC, the NCI or the AACR. Submit a correction